



Remarks

In the Notice dated July 22, 2002, (copy attached as Exhibit A) were requested to comply with the Sequence Listing Rules as set forth in 37 C.F.R §1.821-§1.825. In the Sequence Listing, Applicant has amended field <223> in SEQ ID NOS> 6, 7 and 8 to recite Beta 9-Beta10 loop in FGF-1, FGF-2 and IL-1Beta instead of PCR primers. This amendment to the Sequence Listing is being made to correct and inadvertent error and is only ministerial. Support for this amendment may be found, for example, at page 91, lines 14-27. Thus no new matter has been added.

In compliance with 37 C.F.R §1.821-§1.825, attached hereto is a paper copy of the Sequence Listing , a disk containing a computer readable copy of the Sequence Listing, and a Statement Under 37 C.F.R §1.821-§1.825§1.821(f) stating that the content of the paper copy of the Sequence Listing and computer readable form are the same. Applicant respectfully requests entry of the Sequence listing into the specification.

In the unlikely event that this paper is separated from this sequence listing and the U.S. Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the




filings of this sequence listing to our **Deposit Account No. 03-1952** referencing docket no.

220002057125. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: January 17, 2003

By:


Carol M. Gruppi
Registration No. 37,341

for Catherine M. Polizzi
Registration No. 40,130

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5651
Facsimile: (650) 494-0792